A5002787785- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
- Histone Deacetylase Inhibitors Research
- Glycosylation and Glycoproteins Research
- Bone health and treatments
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- MicroRNA in disease regulation
- Immunotherapy and Immune Responses
- Quinazolinone synthesis and applications
- Chemokine receptors and signaling
- Acute Myeloid Leukemia Research
- RNA modifications and cancer
- Cancer-related Molecular Pathways
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
University of Arkansas for Medical Sciences
2006-2024
Shanghai Normal University
2024
Winthrop Rockefeller Foundation
2020-2024
Hainan Provincial Hospital of Traditional Chinese Medicine
2024
University of Iowa
2014-2023
Central South University
2023
University of Arkansas Medical Center
2023
Institute of Hematology & Blood Diseases Hospital
2016-2019
University of Iowa Hospitals and Clinics
2015-2017
University of Iowa Holden Comprehensive Cancer Center
2015
Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both.We subjected purified plasma from bone marrow patients with newly diagnosed multiple myeloma and control subjects to oligonucleotide microarray profiling biochemical immunohistochemical analyses identify molecular determinants osteolytic lesions.We studied 45 subjects, 36 in whom focal lesions could not be detected by magnetic resonance imaging (MRI), 137 MRI such lesions. Different patterns...
Abstract Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3 subset 1, CRACC, and SLAMF7), cell surface glycoprotein not previously associated with multiple myeloma. To explore the therapeutic potential of HuLuc63 in myeloma, we examined detail expression profile CS1, binding properties to normal malignant cells, antimyeloma activity preclinical models. Experimental Design: was analyzed by gene profiling immunohistochemistry myeloma samples numerous...
Abstract The use of bispecific antibodies (BsAbs) in the treatment relapsed/refractory multiple myeloma (MM) is showing early promising overall response rates heavily pretreated patients. Infectious complications related to BsAbs are not well described. We conducted a pooled analysis that included all single-agent used MM with no prior different BsAbs. A total 1185 patients were treated BsAb studied period (71.6% an agent targeting B-cell maturation antigen (BCMA). Pooled median follow-up...
Abstract With the goal of identifying genes with a differential pattern expression between ovarian serous papillary carcinomas (OSPCs) and normal (NOVA) epithelium using this knowledge for development novel diagnostic therapeutic markers cancer, we used oligonucleotide microarrays probe sets complementary to 12,533 analyze gene profiles 10 primary OSPC cell lines, 2 established lines (UCI‐101, UCI‐107) 5 NOVA epithelial cultures. Unsupervised analysis data identified 129 170 that exhibited...
When shed from the cell surface, heparan sulfate proteoglycan syndecan-1 can facilitate growth, angiogenesis, and metastasis of tumors. Here we report that tumor expression heparanase, an enzyme known to be a potent promoter progression metastasis, regulates both level location within microenvironment by enhancing its synthesis subsequent shedding surface. Heparanase regulation is detected in human myeloma breast cancer lines. This requires presence active enzyme, because mutated forms...
Abstract Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to lack appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) was highly and universally expressed on myeloma cells while having restricted expression normal tissues. Elotuzumab (formerly known as HuLuc63), humanized mAb targeting CS1, is currently phase I clinical trial...